Smartleaf Asset Management
PVLA icon

Smartleaf Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Smartleaf Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.11K Buy
8
+7
+700% +$1.04K ﹤0.01% 3172
2026
Q2 		$155 Hold
1
– – ﹤0.01% 3327
2026
Q1 		$111 Hold
1
– – ﹤0.01% 3390
2025
Q4 		$100 Buy
+1
New +$85 ﹤0.01% 3402

Other funds holding PVLA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

Smartleaf Asset Management's PVLA Position: Q3 2026 in Review

Smartleaf Asset Management increased its Palvella Therapeutics (PVLA) stake by 700% in Q3 2026, buying an estimated $1.04K and bringing the position to 8 shares worth $1.11K. The position accounts for ﹤0.01% of the portfolio, ranked #3172.

Smartleaf Asset Management first reported a position in PVLA in Q4 2025 and has held it in 4 quarters since. 141 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • Smartleaf Asset Management held 8 shares of Palvella Therapeutics worth $1.11K as of Q3 2026.
  • Smartleaf Asset Management bought 7 Palvella Therapeutics shares in Q3 2026, an estimated $1.04K.
  • Palvella Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #3172 holding.
  • Smartleaf Asset Management first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 141 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.